Merck's Losec (omeprazole)
Merck's Losec (omeprazole): March 15 meeting of FDA's Gastrointestinal Drugs Advisory Committee expected to consider long-term once-a-day use of 60 mg omeprazole for Zollinger Ellison Syndrome and for short-term use (four weeks or less) of 40 mg and 20 mg, respectively, in reflux esophagitis and duodenal ulcer. Losec, licenced from Astra, is the first proton pump inhibitor. The Losec NDA was filed in December 1987; the product has been in clinical development for almost a decade.
You may also be interested in...
Bayer notes “significant headwinds" from pandemic hitting its 2020 results likely will continue in 2021, when it t expects core earnings per share slightly below 2020 levels. While noting slumping revenues across its divisions, Bayer said an exception its consumer health business.
After US President Trump said vaccine developers could develop a COVID-19 vaccine faster if it weren't for politics, Moderna CEO Bancel said no political party has asked the company to move faster or slower.
The US green light for Alkindi is a big step for the UK biotech in its bid to become a world-leading specialty endocrinology business.